This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Puma Biotechnology, Inc. Identifier:
First received: April 8, 2009
Last updated: June 27, 2017
Last verified: June 2017
The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.

Condition Intervention Phase
Breast Cancer Drug: neratinib Other: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer

Resource links provided by NLM:

Further study details as provided by Puma Biotechnology, Inc.:

Primary Outcome Measures:
  • disease free survival (DFS) [ Time Frame: Two years ]

Secondary Outcome Measures:
  • Time to Distant Recurrence (TTDR) [ Time Frame: Two through Five years ]
    The time between randomization and the date of the first distant recurrence, or death from breast cancer

  • Disease free survival including ductal carcinoma in situ (DFS-DCIS) [ Time Frame: Two through Five years ]
    The time from randomization to the first occurrence of any DFS event or DCIS

  • Distant disease free survival (DDFS) [ Time Frame: Two through Five years ]
    The time from randomization to the first distant recurrence or death from any cause.

  • Incidence of central nervous system recurrence [ Time Frame: Two through Five years ]
  • Overall survival [ Time Frame: Ten years ]
  • Short and long term safety of neratinib [ Time Frame: Thirteen months ]
  • disease free survival (DFS) [ Time Frame: Five years ]

Enrollment: 2840
Actual Study Start Date: July 9, 2009
Estimated Study Completion Date: November 2020
Primary Completion Date: August 21, 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: neratinib
240 mg orally daily for 1 year
Other Name: HKI-272
Placebo Comparator: 2 Other: placebo
orally daily for 1 year


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.
  • Been treated for early breast cancer with standard of care duration of trastuzumab.
  • Could have been treated neoadjuvantly but have not reached pCR.

Exclusion Criteria:

  • Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.
  • History of heart disease.
  • QTc interval >0.45 seconds
  • History of gastrointestinal disease with diarrhea as the major symptom.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00878709

  Show 493 Study Locations
Sponsors and Collaborators
Puma Biotechnology, Inc.
Study Director: Puma Biotechnology
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Puma Biotechnology, Inc. Identifier: NCT00878709     History of Changes
Other Study ID Numbers: 3144A2-3004
Study First Received: April 8, 2009
Last Updated: June 27, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Puma Biotechnology, Inc.:
HER-2/erbB-2 positive breast cancer
breast cancer
adjuvant therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents processed this record on August 18, 2017